Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease

Hacievlıyagıl, Süleyman Savaş; Günen, Hakan; Mutlu, Levent Cem; Karabulut, Aysun Bay; Temel, İsmail

doi:10.1016/j.rmed.2005.08.022

Cited by 98 publications

(75 citation statements)

References 24 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In vivo, elevated levels of TNF-α have been demonstrated in peripheral blood, bronchial biopsies, induced sputum and BALF of patients with stable COPD compared with control subjects [66][67][68][69][70]. TNF-α has been shown to correlate with body mass index (BMI) and cigarette smoke exposure [71,72] and other inflammatory mediators [73] in COPD. A polymorphism of the promoter region of the TNF-α gene has been implicated in the occurrence, severity, and mortality risk of COPD [74][75][76].…”

Section: Role Of Tnf-α In Asthma and Copdmentioning

confidence: 99%

TNF-α inhibitors in asthma and COPD: We must not throw the baby out with the bath water

Matera

Calzetta

Cazzola

2010

Pulmonary Pharmacology & Therapeutics

113

View full text Add to dashboard Cite

Tumor necrosis factor (TNF)-α, a pleiotropic cytokine that exerts a variety of effects, such as growth promotion, growth inhibition, angiogenesis, cytotoxicity, inflammation, and immunomodulation, has been implicated in several inflammatory conditions. It plays a significant role in many inflammatory diseases of lung. Given that there is significant literature supporting the pathobiologic role of TNF-α in asthma, mainly in severe refractory asthma, and COPD, TNF-α inhibitors (infliximab, golimumab and etanercept) are now regarded as potential new medications in asthma and COPD management. The studies reported in literature indicate that TNF-α inhibitors are effective in a relatively small subgroup of patients with severe asthma, possibly defined by an increased TNF axis, but they seem to be ineffective in COPD, although an observational study demonstrated that TNF-α inhibitors were associated with a reduction in the rate of COPD hospitalisation among patients with COPD receiving these agents to treat their rheumatoid arthritis. These findings require a smart approach because there is still good reason to target TNF-α, perhaps in a more carefully selected patient group. TNF-α treatment should therefore not be thrown out, or abandoned. Indeed, since severe asthma and COPD are heterogeneous diseases that have characteristics that occur with different phenotypes remained poorly characterized and little known about the underlying pathobiology contributing to them, it is likely that definition of these phenotypes and choice of the right outcome measure will allow us to understand which kind of patients can benefit from TNF-α inhibitors.

show abstract

Section: Role Of Tnf-α In Asthma and Copdmentioning

confidence: 99%

TNF-α inhibitors in asthma and COPD: We must not throw the baby out with the bath water

Matera

Calzetta

Cazzola

2010

Pulmonary Pharmacology & Therapeutics

113

View full text Add to dashboard Cite

show abstract

“…Several cytokines, chemokines, eicosanoids, markers of oxidative stress show an increase in COPD compared to asymptomatic smokers, with a further increase during exacerbations. In particular, inflammatory cytokines, including Interleukin-8 (IL-8), Interleukin 6 (IL-6) and Tumour Necrosis Factor-alpha (TNF-α) have been extensively studied and reported increased in sputum of COPD patients compared to normal smokers [51][52][53][54] and their concentrations are related to the severity of the disease [55]. However the inflammatory cytokine Interleukin-10 (IL-10) are reduced in sputum of healthy smokers and, to a greater extent, in smokers with COPD [56], suggesting a role of the imbalance between cytokines with different properties in the smoke-induced lung damage.…”

Section: Inflammatory Mediatorsmentioning

confidence: 99%

Markers of airway inflammation in pulmonary diseases assessed by induced sputum

Dragonieri

Tongoussouva

Zanini

et al. 2016

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

During recent years there has been a growing interest in using non-invasive biomarkers to understand and monitor the airway inflammation in subjects with respiratory tract disorders. To date, the best validated and performing non-invasive biomarkers are measures of inflammation in induced sputum in both cellular and fluid phase, which can provide biological insights into the pathogenesis of respiratory diseases such as asthma and chronic obstructive pulmonary disease. The purpose of this review is to examine the principal literature on the different markers of inflammation in pulmonary diseases assessed by induced sputum analysis in either cellular or fluid phase.

show abstract

“…Elevated levels of cytokines have been reported in BAL specimens of patients with acute lung injury and ARDS [57,58], asthma [59], COPD [60] and cystic fibrosis [61]. Elevated cytokines levels have also been reported in induced sputum samples in patients with COPD [62] and asthma [63]. EBC provides a non-invasive alternative for obtaining ALF samples and has been increasingly studied as a source for monitoring cytokines.…”

Section: Cytokines and Chemokinesmentioning

confidence: 99%

Exhaled Breath Condensates as a Source for Biomarkers for Characterization of Inflammatory Lung Diseases

Bajaj¹,

Ishmael²

2013

JASMI

View full text Add to dashboard Cite

Inflammatory lung diseases such as asthma and chronic obstructive pulmonary disease are common and difficult to diagnose and characterize. This is due in large part to difficulty in obtaining samples directly from the inflamed lung. The collection of lung secretions by traditional methods including bronchoalveolar lavage and induced sputum collection are limited by their invasive nature. Exhaled breath condensate (EBC) is a simple and non-invasive technique of collecting fluid samples, which are representative of airway lining fluid. Advances in collection methods and evolving molecular techniques have led to development of more sensitive assays for existing biomarkers and identification of new biomarkers, which can be potentially useful in monitoring lung inflammation. In this review, we present the current understanding of various biomarkers including small molecules (H 2 O 2 , pH and nitric oxide related biomarkers), lipid mediators (8-isprostane, leukotrienes and prostaglandins), small proteins (cytokines and chemokines) and nucleic acids (DNA and microRNAs). We also discuss the differential profile of biomarkers in recognizing different patterns of lung inflammation. As the sensitivity of methods of EBC improves, this biofluid will play an increasing role in diagnosis and monitoring of lung diseases.

show abstract

Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease

Cited by 98 publications

References 24 publications

TNF-α inhibitors in asthma and COPD: We must not throw the baby out with the bath water

TNF-α inhibitors in asthma and COPD: We must not throw the baby out with the bath water

Markers of airway inflammation in pulmonary diseases assessed by induced sputum

Exhaled Breath Condensates as a Source for Biomarkers for Characterization of Inflammatory Lung Diseases

Contact Info

Product

Resources

About